<DOC>
	<DOCNO>NCT01333436</DOCNO>
	<brief_summary>This study evaluate whether fasting/postprandial serum ApoB-48 level increase diabetic participant compare nondiabetic participant range serum LDL-C level , whether ApoB-48 level use , along LDL-C level , identify potential cardiovascular disease risk .</brief_summary>
	<brief_title>A Study Evaluate Fasting/Postprandial Serum Apolipoprotein B-48 ( ApoB-48 ) Levels Diabetic Participants With Normal Moderately High Low Density Lipoprotein-C ( LDL-C ) Levels ( MK-0653A-259 AM1 )</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>Inclusion criterion : Participant LDLC range ≥100 mg/dL &lt; 160 mg/dL . Patient triglyceride ( TG ) level ≤500 mg/dL . Participant treat lipidlowering agent 6 week prior Visit 1 ( screen period ) . Participant active liver disease persistent unexplained serum transaminase elevation ( ≥2 x upper limit normal [ ULN ] ) Participant increase creatine kinase ( CK ) ( ≥2 x ULN ) . Participant history type 1 diabetes mellitus , ketoacidosis , gestational diabetes mellitus . Participant history alcohol and/or drug abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>